Uaktualnione stanowisko ESC dotyczace stosowania podwojnej terapii przeciwplytkowej w chorobie wiencowej w 2017 roku, przygotowane we wspolpracy z EACTS
Valgimigli, Marco; Bueno, Hector; Byrne, Robert A.et al.
2017 • In Kardiologia Polska, 75 (12), p. 1217-1299
Cardiology; Coronary Artery Disease/drug therapy; Drug Therapy, Combination; Europe; Female; Humans; Male; Platelet Aggregation Inhibitors/therapeutic use; Societies, Medical
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Valgimigli, Marco
Bueno, Hector
Byrne, Robert A.
Collet, Jean-Philippe
Costa, Francesco
Jeppsson, Anders
Juni, Peter
Kastrati, Adnan
Kolh, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path.
Uaktualnione stanowisko ESC dotyczace stosowania podwojnej terapii przeciwplytkowej w chorobie wiencowej w 2017 roku, przygotowane we wspolpracy z EACTS
Alternative titles :
[en] 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
Population Division. Department of Economic and Social Affairs. United Nations. Revision of World Population Prospects. https:// esa un org/unpd/wpp.
Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334(17): 1084-1089, doi: 10.1056/NEJM199604253341702, indexed in Pubmed: 8598866.
McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364(9444): 1519-1521, doi: 10.1016/S0140-6736(04)17275-9, indexed in Pubmed: 15500897.
Valgimigli M, Costa F, Byrne R, et al. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention. 2015; 11(1): 68-74, doi: 10.4244/EIJV11I1A11, indexed in Pubmed: 25982650.
Mozaffarian D, Benjamin EJ, Go AS, et al. Turner MB; the American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016; 133: e38-e360.
Bueno H, Fernández-Avilés F. Use of risk scores in acute coronary syndromes. Heart. 2012; 98(2): 162-168, doi: 10.1136/hear-tjnl-2011-300129, indexed in Pubmed: 22156037.
Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000; 284(7): 835-842, doi: 10.1001/jama.284.7.835, indexed in Pubmed: 10938172.
Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000; 101(22): 2557-2567, doi:10.1161/01.cir.101.22.2557, indexed in Pubmed: 10840005.
Fox KAA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006; 333(7578): 1091, doi: 10.1136/bmj.38985.646481.55, indexed in Pubmed: 17032691.
Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009; 119(14): 1873-1882, doi: 10.1161/CIRCULATIONAHA.108.828541, indexed in Pubmed: 19332461.
Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010; 55(23): 2556-2566, doi: 10.1016/j.jacc.2009.09.076, indexed in Pubmed: 20513595.
Mathews R, Peterson ED, Chen AY, et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. Am J Cardiol. 2011; 107(8): 1136-1143, doi: 10.1016/j.amjcard.2010.12.009, indexed in Pubmed: 21324428.
Costa F, Tijssen JG, Ariotti S, et al. Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. J Am Heart Assoc. 2015; 4(12), doi:10.1161/JAHA.115.002524, indexed in Pubmed: 26643501.
Mahaffey KW, Yang Q, Pieper KS, et al. SYNERGY Trial Investigators. Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. J Gen Intern Med. 2008; 23(3): 310-316, doi: 10.1007/s11606-007-0498-4, indexed in Pubmed: 18196350.
Yeh RW, Secemsky EA, Kereiakes DJ, et al. DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016; 315(16): 1735-1749, doi: 10.1001/jama.2016.3775, indexed in Pubmed: 27022822.
Baber U, Mehran R, Giustino G, et al. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016; 67(19): 2224-2234, doi: 10.1016/j. jacc.2016.02.064, indexed in Pubmed: 27079334.
Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013; 382(9906): 1714-1722, doi: 10.1016/S0140-6736(13)61720-1, indexed in Pubmed:24004642.
Costa F, Klaveren Dv, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017; 389(10073): 1025-1034, doi: 10.1016/s0140-6736(17)30397-5.
Koskinas KC, Räber L, Zanchin T, et al. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv. 2015; 8(5), doi: 10.1161/CIR-CINTERVENTIONS.114.002053, indexed in Pubmed: 25910501.
Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045-1057, doi: 10.1056/NEJ-Moa0904327, indexed in Pubmed: 19717846.
Bertrand ME, Rupprecht HJ, Urban P, et al. CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000; 102(6): 624-629, doi: 10.1161/01. cir.102.6.624, indexed in Pubmed: 10931801.
Campo G, Valgimigli M, Gemmati D, et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol. 2007; 50(12): 1132-1137, doi: 10.1016/j.jacc.2007.04.092, indexed in Pubmed: 17868803.
Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20): 2001-2015, doi: 10.1056/NEJMoa0706482, indexed in Pubmed: 17982182.
Roe MT, Armstrong PW, Fox KAA, et al. TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012; 367(14): 1297-1309, doi: 10.1056/NEJMoa1205512, indexed in Pubmed: 22920930.
Montalescot G, Bolognese L, Dudek D, et al. ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369(11): 999-1010, doi: 10.1056/NEJMoa1308075, indexed in Pubmed: 23991622.
Mauri L, Kereiakes DJ, Yeh RW, et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23): 2155-2166, doi: 10.1056/NEJMoa1409312, indexed in Pubmed: 25399658.
Garratt KN, Weaver WD, Jenkins RG, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement. Circulation. 2015; 131(1): 62-73, doi: 10.1161/CIRCULATIONA-HA.114.013570, indexed in Pubmed:25400062.
Montalescot G, van't Hof AW, Lapostolle F, et al. ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014; 371(11): 1016-1027, doi: 10.1056/NEJMoa1407024, indexed in Pubmed: 25175921.
Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791-1800, doi: 10.1056/NEJMoa1500857, indexed in Pubmed: 25773268.
Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013; 368(15): 1379-1387, doi: 10.1056/NEJMoa1301092, indexed in Pubmed: 23473396.
Sabatine MS, Cannon CP, Gibson CM, et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352(12): 1179-1189, doi: 10.1056/NEJMoa050522, indexed in Pubmed: 15758000.
Chen ZM, Jiang LX, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366(9497): 1607-1621, doi:10.1016/S0140-6736(05)67660-X, indexed in Pubmed: 16271642.
Montalescot G, Wiviott SD, Braunwald E, et al. TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373(9665): 723-731, doi: 10.1016/S0140-6736(09)60441-4, indexed in Pubmed: 19249633.
Roffi M, Patrono C, Collet JP, et al. Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267-315, doi: 10.1093/eurheartj/ehv320, indexed in Pubmed: 26320110.
Valgimigli M. Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified. Circulation. 2014; 130(21): 1891-903; discussion 1903, doi: 10.1161/CIRCULATIONAHA.114.011319, indexed in Pubmed: 25403595.
Collet JP, Silvain J, Bellemain-Appaix A, et al. Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation. 2014; 130(21): 1904-14; discussion 1914, doi: 10.1161/CIRCULATIO-NAHA.114.011320, indexed in Pubmed:25403596.
Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016; 13(1): 11-27, doi:10.1038/nrcardio.2015.113, indexed in Pubmed: 26283269.
Bellemain-Appaix A, O'Connor SA, Silvain J, et al. ACTION Group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA. 2012; 308(23): 2507-2516, doi: 10.1001/jama.2012.50788, indexed in Pubmed: 23287889.
Steinhubl S, Berger P, III JM, et al. Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention. JAMA. 2002; 288(19): 2411, doi: 10.1001/jama.288.19.2411.
Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7): 494-502, doi: 10.1056/NEJMoa010746, indexed in Pubmed: 11519503.
Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011; 32(15): 1854-1864, doi: 10.1093/eur-heartj/ehr204, indexed in Pubmed: 21715717.
Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017; 38(11): 804-810, doi: 10.1093/eur-heartj/ehw525, indexed in Pubmed: 28363222.
Valgimigli M, Gagnor A, Calabró P, et al. MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015; 385(9986): 2465-2476, doi: 10.1016/S0140-6736(15)60292-6, indexed in Pubmed: 25791214.
Ferrante G, Rao SV, Jüni P, et al. Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv. 2016; 9(14): 1419-1434, doi: 10.1016/j.jcin.2016.04.014, indexed in Pubmed: 27372195.
Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71-86, doi: 10.1136/bmj.324.7329.71.
Lorenz RL, Schacky CV, Weber M, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation. Lancet. 1984; 1(8389): 1261-1264, doi: 10.1016/s0140-6736(84)92446-2, indexed in Pubmed: 6144975.
Peters RJG, Mehta SR, Fox KAA, et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003; 108(14): 1682-1687, doi: 10.1161/01. CIR.0000091201.39590.CB, indexed in Pubmed:14504182.
Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005; 95(10): 1218-1222, doi: 10.1016/j. amjcard.2005.01.049, indexed in Pubmed: 15877994.
Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J. 2009; 30(8): 900-907, doi: 10.1093/eurheartj/ehn417, indexed in Pubmed: 18819961.
Xian Y, Wang TY, McCoy LA, et al. Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. Circulation. 2015; 132(3): 174-181, doi: 10.1161/CIRCULATIONAHA.114.014992, indexed in Pubmed: 25995313.
Steinhubl SR, Bhatt DL, Brennan DM, et al. CHARISMA Investigators. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009; 150(6): 379-386, indexed in Pubmed: 19293071.
Mehta SR, Tanguay JF, Eikelboom JW, et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010; 376(9748): 1233-1243, doi: 10.1016/S0140-6736(10)61088-4, indexed in Pubmed: 20817281.
Montalescot G, Drobinski G, Maclouf J, et al. Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation. 1991; 84(5): 2054-2062, doi: 10.1161/01.cir.84.5.2054, indexed in Pubmed: 1934381.
Santilli F, Rocca B, De Cristofaro R, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985; 72(6): 1177-1184, doi:10.1161/01.cir.72.6.1177, indexed in Pubmed: 3933848.
Mahaffey KW, Wojdyla DM, Carroll K, et al. PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011; 124(5): 544-554, doi: 10.1161/CIRCULATIO-NAHA.111.047498, indexed in Pubmed: 21709065.
Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015; 36(27): 1762-1771, doi: 10.1093/eur-heartj/ehv104, indexed in Pubmed:25896078.
Bonello L, Tantry US, Marcucci R, et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010; 56(12): 919-933, doi: 10.1016/j.jacc.2010.04.047, indexed in Pubmed: 20828644.
Collet JP, Cuisset T, Rangé G, et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012; 367(22): 2100-2109, doi: 10.1056/NEJ-Moa1209979, indexed in Pubmed: 23121439.
Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012; 59(24): 2159-2164, doi: 10.1016/j.jacc.2012.02.026, indexed in Pubmed: 22520250.
Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305(11): 1097-1105, doi: 10.1001/jama.2011.290, indexed in Pubmed: 21406646.
Montalescot G, Vicaut E, Collet JP, et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012; 367(22): 2100-2109, doi: 10.1056/NEJ-Moa1209979, indexed in Pubmed: 23121439.
Lim GB. Antiplatelet therapy. ARCTIC leaves platelet testing out in the cold. Nat Rev Cardiol. 2013; 10(1): 2, doi: 10.1038/nrcar-dio.2012.165, indexed in Pubmed: 23165070.
De Miguel Castro A, Nieto AD, Pérez de Prado A. Letter by De Miguel Castro et al regarding article, Circulation. 2012; 125(14): e570; author reply e571-e570; author reply e572, doi: 10.1161/CIR-CULATIONAHA.111.075002, indexed in Pubmed: 22492956.
Cayla G, Cuisset T, Silvain J, et al. ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016; 388(10055): 2015-2022, doi: 10.1016/S0140-6736(16)31323-X, indexed in Pubmed: 27581531.
Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010; 304(16): 1821-1830, doi: 10.1001/jama.2010.1543, indexed in Pubmed: 20978260.
Collet JP, Kerneis M, Hulot JS, et al. GAMMA Investigators. Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. Thromb Haemost. 2016; 115(2): 382-391, doi: 10.1160/TH15-05-0394, indexed in Pubmed: 26423110.
Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012; 379(9827): 1705-1711, doi: 10.1016/S0140-6736(12)60161-5, indexed in Pubmed: 22464343.
Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009; 302(8): 849-857, doi: 10.1001/jama.2009.1232, indexed in Pubmed: 19706858.
Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010; 55(22): 2427-2434, doi: 10.1016/j.jacc.2010.02.031, indexed in Pubmed: 20510210.
Agewall S, Cattaneo M, Collet JP, et al. ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013; 34(23): 1708-13, 1713a, doi: 10.1093/eurheartj/eht042, indexed in Pubmed: 23425521.
Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002; 346(26): 2033-2038, doi: 10.1056/NEJ-Moa012877, indexed in Pubmed: 12087138.
Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374(9684): 119-125, doi: 10.1016/S0140-6736(09)61246-0, indexed in Pubmed: 19577798.
Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008; 48(4): 475-484, doi: 10.1177/0091270008315310, indexed in Pubmed: 18303127.
Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009; 101(4): 714-719, doi: 10.1160/th08-12-0808, indexed in Pubmed: 19350116.
Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51(3): 256-260, doi: 10.1016/j. jacc.2007.06.064, indexed in Pubmed:18206732.
O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009; 374(9694): 989-997, doi: 10.1016/S0140-6736(09)61525-7, indexed in Pubmed:19726078.
Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009; 43(7): 1266-1274, doi: 10.1345/aph.1M051, indexed in Pubmed: 19470853.
Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One. 2015; 10(6): e0124653, doi: 10.1371/journal. pone.0124653, indexed in Pubmed: 26061035.
Vaduganathan M, Cannon CP, Cryer BL, et al. COGENT Investigators, COGENT Investigators, COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363(20): 1909-1917, doi: 10.1056/NEJMoa1007964, indexed in Pubmed: 20925534.
Gargiulo G, Costa F, Ariotti S, et al. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J. 2016; 174: 95-102, doi: 10.1016/j. ahj.2016.01.015, indexed in Pubmed: 26995375.
Goodman SG, Clare R, Pieper KS, et al. Platelet Inhibition and Patient Outcomes Trial Investigators. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012; 125(8): 978-986, doi: 10.1161/CIRCULA-TIONAHA.111.032912, indexed in Pubmed: 22261200.
Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011; 32(23): 2933-2944, doi: 10.1093/eurheartj/ehr422, indexed in Pubmed: 22090660.
de la Coba Ortiz C, Argüelles Arias F, Martín de Argila de Prados C, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva. Rev Esp Enferm Dig. 2016; 108(4): 207-224, doi:10.17235/reed.2016.4232/2016, indexed in Pubmed: 27034082.
Kerneis M, Silvain J, Abtan J, et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv. 2013; 6(2): 158-165, doi: 10.1016/j.jcin.2012.09.012, indexed in Pubmed: 23428007.
Stuckey TD, Kirtane AJ, Brodie BR, et al. ADAPT-DES Investigators, ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013; 382(9892): 614-623, doi:10.1016/S0140-6736(13)61170-8, indexed in Pubmed: 23890998.
Fortuna LA, Pawloski PA, Parker ED, et al. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events. Eur Heart J Cardiovasc Pharmacother. 2016; 2(1): 13-19, doi: 10.1093/ehj-cvp/pvv036, indexed in Pubmed:27533057.
Cannon CP, Harrington RA, James S, et al. PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010; 375(9711): 283-293, doi: 10.1016/S0140-6736(09)62191-7, indexed in Pubmed: 20079528.
Bagai A, Peterson ED, Honeycutt E, et al. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care. 2015; 4(6): 499-508, doi: 10.1177/2048872614564082, indexed in Pubmed: 25515725.
Clemmensen P, Grieco N, Ince H, et al. MULTIPRAC study investigators. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel-the European MULTIPRAC Registry. Eur Heart J Acute Cardiovasc Care. 2015; 4(3): 220-229, doi: 10.1177/2048872614547449, indexed in Pubmed:25182465.
Alexopoulos D, Xanthopoulou I, Deftereos S, et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J. 2014; 167(1): 68-76.e2, doi:10.1016/j.ahj.2013.10.010, indexed in Pubmed: 24332144.
Franchi F, Faz GT, Rollini F, et al. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. JACC Cardiovasc Interv. 2016; 9(11): 1089-1098, doi: 10.1016/j.jcin.2016.02.039, indexed in Pubmed: 27013060.
Angiolillo DJ, Curzen N, Gurbel P, et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). J Am Coll Cardiol. 2014; 63(15): 1500-1509, doi: 10.1016/j.jacc.2013.11.032, indexed in Pubmed: 24333493.
Angiolillo DJ, Saucedo JF, Deraad R, et al. SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010; 56(13): 1017-1023, doi:10.1016/j.jacc.2010.02.072, indexed in Pubmed: 20846599.
Bhatt DL, Fox KAA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16): 1706-1717, doi: 10.1056/NEJMoa060989, indexed in Pubmed: 16531616.
Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation. 1998; 98(16): 1597-1603, doi: 10.1161/01.cir.98.16.1597, indexed in Pubmed: 9778323.
Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998; 98(20): 2126-2132, doi:10.1161/01.cir.98.20.2126, indexed in Pubmed: 9815866.
Yeh RW, Kereiakes DJ, Steg PG, et al. DAPT Study Investigators. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015; 65(20): 2211-2221, doi: 10.1016/j. jacc.2015.03.003, indexed in Pubmed: 25787199.
Costa F, Vranckx P, Leonardi S, et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. Eur Heart J. 2015; 36(20): 1242-1251, doi: 10.1093/eurheartj/ehv038, indexed in Pubmed:25718355.
Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012; 125(3): 505-513, doi: 10.1161/CIRCULATIO-NAHA.111.059022, indexed in Pubmed: 22179532.
Valgimigli M, Campo G, Monti M, et al. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012; 125(16): 2015-2026, doi: 10.1161/CIRCULATIONAHA.111.071589, indexed in Pubmed: 22438530.
Gilard M, Barragan P, Noryani AAL, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015; 65(8): 777-786, doi: 10.1016/j. jacc.2014.11.008, indexed in Pubmed: 25461690.
Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014; 64(20): 2086-2097, doi: 10.1016/j. jacc.2014.09.008, indexed in Pubmed: 25236346.
Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015; 36(20): 1252-1263, doi: 10.1093/eurheartj/ehu523, indexed in Pubmed: 25616646.
Kim BK, Hong MK, Shin DH, et al. RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012; 60(15): 1340-1348, doi: 10.1016/j. jacc.2012.06.043, indexed in Pubmed: 22999717.
Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310: 2510-2522, doi: 10.1001/jama.2013.282183.
Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015; 385(9985): 2371-2382, doi: 10.1016/S0140-6736(15)60263-X, indexed in Pubmed: 25777667.
Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015; 350: h1618, doi: 10.1136/bmj.h1618, indexed in Pubmed: 25883067.
Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015; 65(13): 1298-1310, doi: 10.1016/j.jacc.2015.01.039, indexed in Pubmed: 25681754.
Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med. 2015; 372(14): 1371-1374, doi: 10.1056/nejmc1501195.
Park SJ, Lee CW, Ahn JM, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014; 129(3): 304-312, doi: 10.1161/CIR-CULATIONAHA.113.003303, indexed in Pubmed: 24097439.
Collet JP, Silvain J, Barthélémy O, et al. ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014; 384(9954): 1577-1585, doi: 10.1016/S0140-6736(14)60612-7, indexed in Pubmed: 25037988.
Bittl JA, Baber U, Bradley SM, et al. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016; 68(10): 1116-1139, doi: 10.1016/j.jacc.2016.03.512, indexed in Pubmed: 27036919.
Valgimigli M, Borghesi M, Tebaldi M, et al. PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013; 34(12): 909-919, doi:10.1093/eurheartj/ehs460, indexed in Pubmed: 23315904.
Hermiller JB, Krucoff MW, Kereiakes DJ, et al. DAPT Study Investigators. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016; 9(2): 138-147, doi: 10.1016/j.jcin.2015.10.001, indexed in Pubmed: 26793956.
Sharma A, Sharma SK, Vallakati A, et al. Duration of dual antiplatelet therapy after various drug-eluting stent implantation. Int J Cardiol. 2016; 215: 157-166, doi: 10.1016/j.ijcard.2016.04.118, indexed in Pubmed: 27116326.
Palmerini T, Stone GW. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence. Eur Heart J. 2016; 37(4): 353-364, doi: 10.1093/eurheartj/ehv712, indexed in Pubmed: 26795933.
Ellis SG, Kereiakes DJ, Metzger DC, et al. ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015; 373(20): 1905-1915, doi: 10.1056/NEJMoa1509038, indexed in Pubmed: 26457558.
Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016; 387(10018): 537-544, doi: 10.1016/S0140-6736(15)00979-4, indexed in Pubmed: 26597771.
Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016; 388(10059): 2479-2491, doi: 10.1016/S0140-6736(16)32050-5, indexed in Pubmed: 27806897.
Räber L, Brugaletta S, Yamaji K, et al. Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. J Am Coll Cardiol. 2015; 66(17): 1901-1914, doi: 10.1016/j.jacc.2015.08.853, indexed in Pubmed: 26493663.
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. RIBS IV Study Investigators (under auspices of Interventional Cardiology Working Group of Spanish Society of Cardiology). A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. J Am Coll Cardiol. 2015; 66(1): 23-33, doi: 10.1016/j.jacc.2015.04.063, indexed in Pubmed: 26139054.
Xu Bo, Gao R, Wang J, et al. PEPCAD China ISR Trial Investigators. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014; 7(2): 204-211, doi: 10.1016/j.jcin.2013.08.011, indexed in Pubmed: 24556098.
Byrne RA, Neumann FJ, Mehilli J, et al. ISAR-DESIRE 3 investigators. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013; 381(9865): 461-467, doi: 10.1016/S0140-6736(12)61964-3, indexed in Pubmed: 23206837.
Wöhrle hr, Zadura M, Mobius-Winkler S, et al. SeQuent Please World Wide Registry: clinical results of SeQuent Please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol. 2012; 18: 1733-1738.
Han Y, Xu Bo, Xu K, et al. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial. Circ Cardiovasc Interv. 2016; 9(2): e003145, doi: 10.1161/CIR-CINTERVENTIONS.115.003145, indexed in Pubmed: 26858080.
Hong SJ, Shin DH, Kim JS, et al. IVUS-XPL Investigators. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. JACC Cardiovasc Interv. 2016; 9(14): 1438-1446, doi: 10.1016/j.jcin.2016.04.036, indexed in Pubmed: 27212028.
Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT Study Investigators, Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015; 313(11): 1113-1121, doi: 10.1001/jama.2015.1671, indexed in Pubmed: 25781440.
Urban P, Meredith IT, Abizaid A, et al. LEADERS FREE Investigators. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med. 2015; 373(21): 2038-2047, doi: 10.1056/NEJMoa1503943, indexed in Pubmed: 26466021.
Valgimigli M, Patialiakas A, Thury A, et al. ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015; 65(8): 805-815, doi: 10.1016/j.jacc.2014.11.053, indexed in Pubmed: 25720624.
Valgimigli M, Sabate M, Kaiser C, et al. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ. 2014; 349(nov04 12): g6427-g6427, doi: 10.1136/bmj.g6427.
Bønaa KH, Mannsverk J, Wiseth R, et al. NORSTENT Investigators. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N Engl J Med. 2016; 375(13): 1242-1252, doi: 10.1056/NEJ-Moa1607991, indexed in Pubmed: 27572953.
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014; 63(14): 1378-1386, doi: 10.1016/j.jacc.2013.12.006, indexed in Pubmed: 24412457.
Byrne RA, Serruys PW, Baumbach A, et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J. 2015; 36(38): 2608-2620, doi:10.1093/eurheartj/ehv203, indexed in Pubmed: 26071600.
Bhatt DL, Flather MD, Hacke W, et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49(19): 1982-1988, doi: 10.1016/j.jacc.2007.03.025, indexed in Pubmed: 17498584.
Wiviott S, White H, Ohman E, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013; 382(9892): 605-613, doi: 10.1016/s0140-6736(13)61451-8.
Scirica BM, Bonaca MP, Braunwald E, et al. TRA 2°P-TIMI 50 Steering Committee Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012; 380(9850): 1317-1324, doi: 10.1016/S0140-6736(12)61269-0, indexed in Pubmed: 22932716.
Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008; 51(7): 690-697, doi: 10.1016/j. jacc.2007.10.040, indexed in Pubmed: 18279731.
Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016; 37(14): 1133-1142, doi: 10.1093/eur-heartj/ehv531, indexed in Pubmed:26491109.
Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016; 67(23): 2719-2728, doi: 10.1016/j.jacc.2016.03.524, indexed in Pubmed: 27046162.
Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016; 37(4): 390-399, doi:10.1093/eurheartj/ehv443, indexed in Pubmed: 26324537.
Costa F, Adamo M, Ariotti S, et al. Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis. Int J Cardiol. 2015; 201: 179-181, doi: 10.1016/j.ijcard.2015.08.058, indexed in Pubmed: 26298373.
Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017; 38(14): 1034-1043, doi: 10.1093/eurheartj/ehw627, indexed in Pubmed: 28110296.
Magnani G, Storey RF, Steg G, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016; 37(4): 400-408, doi: 10.1093/eurheartj/ehv482, indexed in Pubmed:26443023.
Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016; 67(23): 2732-2740, doi: 10.1016/j.jacc.2016.03.529, indexed in Pubmed: 27046160.
Vranckx P, Valgimigli M, Windecker S, et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention. 2016; 12(10): 1239-1245, doi: 10.4244/EIJY15M11_07, indexed in Pubmed: 26606735.
Fox KAA, Mehta SR, Peters R, et al. Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004; 110(10): 1202-1208, doi: 10.1161/01.CIR.0000140675.85342.1B, indexed in Pubmed: 15313956.
Verma S, Goodman SG, Mehta SR, et al. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg. 2015; 15: 112, doi: 10.1186/s12893-015-0096-z, indexed in Pubmed: 26467661.
Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg. 2013; 28(2): 109-116, doi: 10.1111/jocs.12074, indexed in Pubmed: 23488578.
Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011; 57(6): 672-684, doi:10.1016/j.jacc.2010.10.029, indexed in Pubmed: 21194870.
Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012; 60(5): 388-396, doi: 10.1016/j.jacc.2012.03.030, indexed in Pubmed: 22633653.
Hansson EC, Jidéus L, Åberg B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J. 2016; 37(2): 189-197, doi: 10.1093/eurheartj/ehv381, indexed in Pubmed: 26330426.
Tomšič A, Schotborgh MA, Manshanden JSJ, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg. 2016; 50(5): 849-856, doi: 10.1093/ejcts/ezw149, indexed in Pubmed: 27174551.
Pickard AS, Becker RC, Schumock GT, et al. Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. Pharmacotherapy. 2008; 28(3): 376-392, doi: 10.1592/phco.28.3.376, indexed in Pubmed: 18294117.
Purkayastha S, Athanasiou T, Malinovski V, et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart. 2006; 92(4): 531-532, doi: 10.1136/hrt.2004.058396, indexed in Pubmed: 16537769.
Kolh P, Windecker S, Alfonso F, et al. European Society of Cardiology Committee for Practice Guidelines, EACTS Clinical Guidelines Committee, Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery, European Association of Percutaneous Cardiovascular Interventions, Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014; 35(37): 2541-2619, doi: 10.1093/eurheartj/ehu278, indexed in Pubmed: 25173339.
Ferraris VA, Saha SP, Oestreich JH, et al. Society of Thoracic Surgeons. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg. 2012; 94(5): 1761-1781, do-i:10.1016/j.athoracsur.2012.07.086, indexed in Pubmed: 23098967.
Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009; 30(16): 1964-1977, doi: 10.1093/eurheartj/ehp296, indexed in Pubmed: 19633016.
Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25): 2577-2585, doi:10.1161/CIRCULATIONAHA.109.912550, indexed in Pubmed: 19923168.
Gherli R, Mariscalco G, Dalén M, et al. Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting. JAMA Cardiol. 2016; 1(8): 921-928, doi: 10.1001/jamacardio.2016.3028, indexed in Pubmed: 27653165.
Steg PhG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569-2619, doi: 10.1093/eur-heartj/ehs215, indexed in Pubmed: 22922416.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893-2962, doi: 10.1093/eurhe-artj/ehw210, indexed in Pubmed: 27567408.
Hastings S, Myles P, McIlroy D. Aspirin and coronary artery surgery: a systematic review and meta-analysis. Br J Anaesth. 2015; 115(3): 376-385, doi:10.1093/bja/aev164, indexed in Pubmed: 26082471.
Myles PS, Smith JA, Forbes A, et al. ATACAS Investigators of the ANZCA Clinical Trials Network. Stopping vs. Continuing Aspirin before Coronary Artery Surgery. N Engl J Med. 2016; 374(8): 728-737, doi: 10.1056/NEJMoa1507688, indexed in Pubmed: 26933848.
Dacey L, Munoz J, Johnson E, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. The Annals of Thoracic Surgery. 2000; 70(6): 1986-1990, doi: 10.1016/s0003-4975(00)02133-0.
Malm CJ, Hansson EC, Åkesson J, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth. 2014; 112(3): 570-575, doi: 10.1093/bja/aet339, indexed in Pubmed: 24148324.
Martin AC, Berndt C, Calmette L, et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study. Eur J Anaesthesiol. 2016; 33(5): 361-367, doi: 10.1097/EJA.0000000000000348, indexed in Pubmed: 26351831.
O'Connor SA, Amour J, Mercadier A, et al. ACTION Study Group. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Circ Cardiovasc Interv. 2015; 8(11): e002786, doi:10.1161/CIRCINTERVENTIONS.115.002786, indexed in Pubmed: 26553698.
Malm CJ, Hansson EC, Åkesson J, et al. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study. Br J Anaesth. 2016; 117(3): 309-315, doi: 10.1093/bja/aew189, indexed in Pubmed: 27543525.
Storey RF, Bliden KP, Ecob R, et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost. 2011; 9(9): 1730-1737, doi: 10.1111/j.1538-7836.2011.04419.x, indexed in Pubmed:21707911.
Hansson EC, Malm CJ, Hesse C, et al. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery. Eur J Cardiothorac Surg. 2017; 51(4): 633-637, doi: 10.1093/ejcts/ezw373, indexed in Pubmed: 28007881.
Kwak YL, Kim JC, Choi YS, et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol. 2010; 56(24): 1994-2002, doi: 10.1016/j.jacc.2010.03.108, indexed in Pubmed: 21126640.
Ranucci M, Baryshnikova E, Soro G, et al. Surgical and Clinical Outcome Research (SCORE) Group. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg. 2011; 91(1): 123-129, doi: 10.1016/j. athoracsur.2010.09.022, indexed in Pubmed: 21172499.
Ranucci M, Colella D, Baryshnikova E, et al. Surgical and Clinical Outcome Research (SCORE) Group. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth. 2014; 113(6): 970-976, doi: 10.1093/bja/aeu315, indexed in Pubmed:25209096.
Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv. 2012; 5(2): 261-269, doi: 10.1161/CIRCINTERVENTIONS.111.967208, indexed in Pubmed: 22396581.
Vries MJA, Bouman HJ, Olie RH, et al. Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. Eur Heart J Cardiovasc Pharmacother. 2017; 3(1): 11-17, doi: 10.1093/ehjcvp/pvw026, indexed in Pubmed: 27609198.
Nocerino AG, Achenbach S, Taylor AJ. Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. Am J Cardiol. 2013; 112(10): 1576-1579, doi: 10.1016/j.amjcard.2013.07.017, indexed in Pubmed: 24035160.
Mannacio VA, Di Tommaso L, Antignan A, et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart. 2012; 98(23): 1710-1715, doi: 10.1136/he-artjnl-2012-302449, indexed in Pubmed: 22942294.
Morrow D, Braunwald E, Bonaca M, et al. Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine. 2012; 366(15): 1404-1413, doi: 10.1056/nejmoa1200933.
James SK, Roe MT, Cannon CP, et al. PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011; 342: d3527, doi:10.1136/bmj.d3527, indexed in Pubmed: 21685437.
Prami T, Khanfir H, Deleskog A, et al. Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland. BMJ Open. 2016; 6(11): e012604, doi: 10.1136/bmjopen-2016-012604, indexed in Pubmed: 27881527.
Iannaccone M, Quadri G, Taha S, et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2016; 17(10): 1128-1137, doi: 10.1093/ehjci/jev283, indexed in Pubmed: 26508517.
Sørensen R, Hansen M, Abildstrom S, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009; 374(9706): 1967-1974, doi:10.1016/s0140-6736(09)61751-7.
Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170(16): 1433-1441, doi: 10.1001/archinternmed.2010.271, indexed in Pubmed: 20837828.
Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013; 127(5): 634-640, doi: 10.1161/CIRCULATIO-NAHA.112.115386, indexed in Pubmed:23271794.
Oldgren J, Budaj A, Granger CB, et al. RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32(22): 2781-2789, doi: 10.1093/eurhe-artj/ehr113, indexed in Pubmed:21551462.
Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012; 380(9855): 1749-1758, doi: 10.1016/S0140-6736(12)60986-6, indexed in Pubmed: 23036896.
Barnes GD, Gu X, Haymart B, et al. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. Thromb Res. 2014; 134(2): 294-299, doi: 10.1016/j.thromres.2014.05.034, indexed in Pubmed: 24929840.
Roldán V, Marín F, Manzano-Fernández S, et al. The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2013; 62(23): 2199-2204, doi:10.1016/j. jacc.2013.08.1623.
Hijazi Z, Oldgren J, Lindbäck J, et al. ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016; 387(10035): 2302-2311, doi: 10.1016/S0140-6736(16)00741-8, indexed in Pubmed: 27056738.
Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375(25): 2423-2434, doi: 10.1056/NEJMoa1611594, indexed in Pubmed: 27959713.
Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013; 61(20): 2060-2066, doi: 10.1016/j. jacc.2013.02.036, indexed in Pubmed: 23524219.
Dewilde WJM, Oirbans T, Verheugt FWA, et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381(9872): 1107-1115, doi: 10.1016/S0140-6736(12)62177-1, indexed in Pubmed: 23415013.
Gibson CM, Pinto DS, Chi G, et al. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 2017; 135(4): 323-333, doi:10.1161/CIRCULATIONAHA.116.025783, indexed in Pubmed: 27881555.
Fiedler KA, Maeng M, Mehilli J, et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015; 65(16): 1619-1629, doi: 10.1016/j.jacc.2015.02.050, indexed in Pubmed: 25908066.
Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012; 126(10): 1185-1193, doi:10.1161/CIRCULATIONAHA.112.114967, indexed in Pubmed: 22869839.
Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013; 62(11): 981-989, doi: 10.1016/j.jacc.2013.05.029, indexed in Pubmed: 23747760.
Lamberts M, Gislason GH, Lip GYH, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014; 129(15): 1577-1585, doi: 10.1161/CIRCULATIONAHA.113.004834, indexed in Pubmed:24470482.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-1151, doi: 10.1056/NEJMoa0905561, indexed in Pubmed: 19717844.
Halperin JL, Hankey GJ, Wojdyla DM, et al. ROCKET AF Steering Committee and Investigators, ROCKET AF Investigators, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-891, doi: 10.1056/NEJ-Moa1009638, indexed in Pubmed: 21830957.
Granger CB, Alexander JH, McMurray JJ, et al. Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992, doi: 10.1056/nejmoa1107039, indexed in Pubmed: 21870978.
Link MS, Giugliano RP, Ruff CT, et al. ENGAGE AF-TIMI 48 Investigators, ENGAGE AF-TIMI 48 Investigators, ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093-2104, doi: 10.1056/NEJMoa1310907, indexed in Pubmed: 24251359.
Richman JS, Graham LA, DeRussy A, et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA. 2013; 310(14): 1462-1472, doi: 10.1001/jama.2013.278787, indexed in Pubmed: 24101118.
Ariotti S, Adamo M, Costa F, et al. ZEUS Investigators. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. JACC Cardiovasc Interv. 2016; 9(5): 426-436, doi:10.1016/j.jcin.2015.11.015, indexed in Pubmed: 26965932.
Kristensen SD, Knuuti J, Saraste A, et al. Funck-Brentano C; Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: car- diovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014; 35: 2383-2431, doi:10.1093/eurheartj/ehu282.
Chee YL, Crawford JC, Watson HG, et al. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol. 2008; 140(5): 496-504, doi: 10.1111/j.1365-2141.2007.06968.x, indexed in Pubmed: 18275427.
Fleisher LA, Fleischmann KE, Auerbach AD, et al. American College of Cardiology, American Heart Association. 2014 ACC/ AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014; 64: e77-137.
Siller-Matula JM, Petre A, Delle-Karth G, et al. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care. 2015 [Epub ahead of print], doi: 10.1177/2048872615585516, indexed in Pubmed: 25943554.
Glance LG, Lustik SJ, Hannan EL, et al. The Surgical Mortality Probability Model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg. 2012; 255(4): 696-702, doi: 10.1097/SLA.0b013e31824b45af, indexed in Pubmed: 22418007.
Rossini R, Musumeci G, Visconti LO, et al. Italian Society of Invasive Cardiology (SICI-GISE), Italian Association of Hospital Cardiologists (ANMCO), Italian Society for Cardiac Surgery (SICCH), Italian Society of Vascular and Endovascular Surgery (SICVE), Italian Association of Hospital Surgeons (ACOI), Italian Society of Surgery (SIC), Italian Society of Anaesthesia and Intensive Care Medicine (SIAARTI), Lombard Society of Surgery (SLC), Italian Society of Maxillofacial Surgery (SICMF), Italian Society of Reconstructive Plastic Surgery and Aesthetics (SICPRE), Italian Society of Thoracic Surgeons (SICT), Italian Society of Urology (SIU), Italian Society of Orthopaedics and Traumatology (SIOT), Italian Society of Periodontology (SIdP), Italian Federation of Scientific Societies of Digestive System Diseases Lombardia (FISMAD), Association of Obstetricians Gynaecologists Italian Hospital Lombardia (AOGOI), Society of Ophthalmology Lombardia (SOL). Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention. 2014; 10(1): 38-46, doi: 10.4244/EIJV10I1A8, indexed in Pubmed: 24832636.
Chapman TW, Bowley DM, Lambert AW, et al. Haemorrhage associated with combined clopidogrel and aspirin therapy. Eur J Vasc Endovasc Surg. 2001; 22(5): 478-479, doi: 10.1053/ejvs.2001.1506, indexed in Pubmed: 11735194.
Ernst A, Eberhardt R, Wahidi M, et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest. 2006; 129(3): 734-737, doi: 10.1378/chest.129.3.734, indexed in Pubmed: 16537875.
Moore M, Power M. Perioperative hemorrhage and combined clopidogrel and aspirin therapy. Anesthesiology. 2004; 101(3): 792-794, doi:10.1097/00000542-200409000-00030, indexed in Pubmed: 15329606.
Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005; 257(5): 399-414, doi: 10.1111/j.1365-2796.2005.01477.x, indexed in Pubmed: 15836656.
Merritt J, Bhatt D. The Efficacy and Safety of Perioperative Antiplatelet Therapy. Journal of Thrombosis and Thrombolysis. 2004; 17(1): 21-27, doi:10.1023/b:thro.0000036025.07348.f1.
Berger PB, Kleiman NS, Pencina MJ, et al. EVENT Investigators. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv. 2010; 3(9): 920-927, doi: 10.1016/j. jcin.2010.03.021, indexed in Pubmed: 20850090.
van Kuijk JP, Flu WJ, Schouten O, et al. Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents. Am J Cardiol. 2009; 104(9): 1229-1234, doi: 10.1016/j. amjcard.2009.06.038, indexed in Pubmed: 19840567.
Diamantis T, Tsiminikakis N, Skordylaki A, et al. Alterations of hemostasis after laparoscopic and open surgery. Hematology. 2007; 12(6): 561-570, doi: 10.1080/10245330701554623, indexed in Pubmed: 17852431.
Rajagopalan S, Ford I, Bachoo P, et al. Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery. J Thromb Haemost. 2007; 5(10): 2028-2035, doi: 10.1111/j.1538-7836.2007.02694.x, indexed in Pubmed:17650080.
Grines CL, Bonow RO, Casey DE, et al. American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, American Dental Association, American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007; 115(6): 813-818, doi: 10.1161/CIRCULATIONAHA.106.180944, indexed in Pubmed: 17224480.
Levine GN, Bates ER, Blankenship JC, et al. American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58: e44-122.
Fleisher LA, Beckman JA, Brown KA, et al. Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL,, Tarkington LG, Yancy CW. ACC/ AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol. 2007; 50: e159-241.
Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol. 2008; 51(23): 2220-2227, doi: 10.1016/j.jacc.2008.01.063, indexed in Pubmed: 18534267.
Petersen JL, Barron JJ, Hammill BG, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007; 297(2): 159-168, doi: 10.1001/jama.297.2.joc60179, indexed in Pubmed: 17148711.
Navarese EP, Tandjung K, Claessen B, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013; 347: f6530, doi:10.1136/bmj.f6530, indexed in Pubmed: 24196498.
Egholm G, Kristensen S, Thim T, et al. Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation. J Am Coll Cardiol. 2016; 68(24): 2622-2632, doi: 10.1016/j. jacc.2016.09.967.
Holcomb CN, Graham LA, Richman JS, et al. The Incremental Risk of Coronary Stents on Postoperative Adverse Events: A Matched Cohort Study. Ann Surg. 2016; 263(5): 924-930, doi: 10.1097/SLA.0000000000001246, indexed in Pubmed: 25894416.
Kolh P, Windecker S, Alfonso F, et al. European Society of Cardiology Committee for Practice Guidelines, EACTS Clinical Guidelines Committee, Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery, European Association of Percutaneous Cardiovascular Interventions. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014; 46(4): 517-592, doi: 10.1093/ejcts/ezu366, indexed in Pubmed: 25173601.
Savonitto S, D'Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010; 104(3): 285-291, doi:10.1093/bja/aep373, indexed in Pubmed: 20047898.
Qamar A, Bhatt DL. Current status of data on cangrelor. Pharmacol Ther. 2016; 159: 102-109, doi: 10.1016/j.pharmthera.2016.01.004, indexed in Pubmed: 26802900.
Angiolillo DJ, Firstenberg MS, Price MJ, et al. BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012; 307(3): 265-274, doi: 10.1001/jama.2011.2002, indexed in Pubmed: 22253393.
Abualsaud AO, Eisenberg MJ. Perioperative management of patients with drug-eluting stents. JACC Cardiovasc Interv. 2010; 3(2): 131-142, doi:10.1016/j.jcin.2009.11.017, indexed in Pubmed: 20170869.
Dimitrova G, Tulman DB, Bergese SD. Perioperative management of antiplatelet therapy in patients with drug-eluting stents. HSR Proc Intensive Care Cardiovasc Anesth. 2012; 4(3): 153-167, indexed in Pubmed: 23439793.
Kałuza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000; 35(5): 1288-1294, doi: 10.1016/s0735-1097(00)00521-0, indexed in Pubmed: 10758971.
van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009; 53(16): 1399-1409, doi: 10.1016/j. jacc.2008.12.055, indexed in Pubmed: 19371823.
Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293(17): 2126-2130, doi: 10.1001/jama.293.17.2126, indexed in Pubmed: 15870416.
Bay C, Cyr PL, Jensen I. Estimating The Value Of Cangrelor From Eliminating Preloading In Coronary Artery Bypass Graft (Cabg) Patients. Value Health. 2014; 17(7): A480, doi: 10.1016/j. jval.2014.08.1389, indexed in Pubmed: 27201397.
De Servi S, Morici N, Boschetti E, et al. Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients. Vascul Pharmacol. 2016; 80: 85-90, doi: 10.1016/j.vph.2015.11.085, indexed in Pubmed: 26657879.
Voeltz MD, Manoukian SV. Cangrelor in patients undergoing cardiac surgery: the BRIDGE study. Expert Rev Cardiovasc Ther. 2013; 11(7): 811-816, doi: 10.1586/14779072.2013.811972, indexed in Pubmed: 23895024.
Sawaya FJ, Morice MC, Spaziano M, et al. Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials. Catheter Cardiovasc Interv. 2017; 89(2): 178-189, doi: 10.1002/ccd.26653, indexed in Pubmed: 27426936.
Gargiulo G, Ariotti S, Santucci A, et al. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. JACC Cardiovasc Interv. 2016; 9(17): 1780-1789, doi: 10.1016/j.jcin.2016.05.046, indexed in Pubmed: 27544007.
Meredith IT, Tanguay JF, Kereiakes DJ, et al. Jr, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators. Diabetes mellitus and preven- tion of late myocardial infarction after coronary stenting in the Randomized Dual Antiplatelet Therapy study. Circulation. 2016; 133: 1772-1782.
Steg PhG, Bhatt DL, Wilson PWF, et al. REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297(11): 1197-1206, doi: 10.1001/jama.297.11.1197, indexed in Pubmed: 17374814.
Cacoub PP, Bhatt DL, Steg PG, et al. CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009; 30(2): 192-201, doi: 10.1093/eurheartj/ehn534, indexed in Pubmed: 19136484.
Bonaca MP, Gutierrez JA, Creager MA, et al. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation. 2016; 133(10): 997-1005, doi: 10.1161/CIRCULATIO-NAHA.115.019355, indexed in Pubmed: 26826179.
Franzone A, Piccolo R, Gargiulo G, et al. Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial. JAMA Cardiol. 2016; 1(7): 795-803, doi: 10.1001/jamacar-dio.2016.2811, indexed in Pubmed: 27572001.
Giustino G, Chieffo A, Palmerini T, et al. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol. 2016; 68(17): 1851-1864, doi: 10.1016/j.jacc.2016.07.760, indexed in Pubmed: 27595509.
Armstrong EJ, Sab S, Singh GD, et al. Predictors and outcomes of recurrent stent thrombosis: results from a multicenter registry. JACC Cardiovasc Interv. 2014; 7(10): 1105-1113, doi: 10.1016/j. jcin.2014.05.017, indexed in Pubmed: 25341707.
Halvorsen S, Storey RF, Rocca B, et al. ESC Working Group on Thrombosis. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2017; 38(19): 1455-1462, doi: 10.1093/eurheartj/ehw454, indexed in Pubmed: 27789570.
Amin AP, Bachuwar A, Reid KJ, et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol. 2013; 61(21): 2130-2138, doi: 10.1016/j.jacc.2013.02.044, indexed in Pubmed: 23541975.
Kristensen SD, Laut KG, Fajadet J, et al. European Association for Percutaneous Cardiovascular Interventions. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J. 2014; 35: 1957-1970.
Organization for Economic Co-operation and Development. OECD Health Statistics 2016. http://www oecd org/els/health-systems/health-data htm (1 January 2017).
British Cardiovascular Intervention Society. http://www.bcis.org.uk (1 January 2017).
Pilgrim T, Vranckx P, Valgimigli M, et al. Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. Am Heart J. 2016; 175: 56-65, doi: 10.1016/j.ahj.2016.01.021, indexed in Pubmed: 27179724.
Taniwaki M, Stefanini GG, Silber S, et al. RESOLUTE All-Comers Investigators. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014; 63(16): 1617-1625, doi: 10.1016/j. jacc.2013.12.036, indexed in Pubmed: 24530680.
McAllister KSL, Ludman PF, Hulme W, et al. British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research. A contemporary risk model for predicting 30-day mortality following percutaneous coronary intervention in England and Wales. Int J Cardiol. 2016; 210: 125-132, doi: 10.1016/j.ijcard.2016.02.085, indexed in Pubmed: 26942330.
Brennan JM, Curtis JP, Dai D, et al. National Cardiovascular Data Registry. Enhanced mortality risk prediction with a focus on high-risk percutaneous coronary intervention: results from 1,208,137 procedures in the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2013; 6(8): 790-799, doi: 10.1016/j.jcin.2013.03.020, indexed in Pubmed: 23968699.
Byrne RA, Serruys PW, Baumbach A, et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J. 2015; 36(38): 2608-2620, doi: 10.1093/eurheartj/ehv203, indexed in Pubmed: 26071600.
Serruys PW, Morice MC, Kappetein AP, et al. SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009; 360(10): 961-972, doi: 10.1056/NEJMoa0804626, indexed in Pubmed: 19228612.
Taniwaki M, Windecker S, Zaugg S, et al. The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J. 2015; 36(32): 2167-2176, doi: 10.1093/eurheartj/ehv227, indexed in Pubmed: 26040806.
Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007; 116(21): 2391-2398, doi: 10.1161/CIRCULATIONAHA.107.707331, indexed in Pubmed: 17984377.
Räber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012; 125(9): 1110-1121, doi: 10.1161/CIR-CULATIONAHA.111.058560, indexed in Pubmed: 22302840.
Yamaji K, Kimura T, Morimoto T, et al. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv. 2010; 3(5): 468-475, doi: 10.1161/CIRCINTERVENTIONS.110.958249, indexed in Pubmed: 20823392.
Räber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011; 123(24): 2819-28, 6 p following 2828, doi: 10.1161/CIRCULATIONAHA.110.004762, indexed in Pubmed: 21646500.
Mohr F, Morice MC, Kappetein A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013; 381(9867): 629-638, doi: 10.1016/s0140-6736(13)60141-5.
Mauri L, Kereiakes DJ, Yeh RW, et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23): 2155-2166, doi: 10.1056/NEJMoa1409312, indexed in Pubmed: 25399658.
Morice MC, Serruys PW, Sousa JE, et al. RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346(23): 1773-1780, doi: 10.1056/NEJMoa012843, indexed in Pubmed: 12050336.
Moses JW, Leon MB, Popma JJ, et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349(14): 1315-1323, doi: 10.1056/NEJMoa035071, indexed in Pubmed: 14523139.
Lansky AJ, Costa RA, Mooney M, et al. TAXUS-IV Investigators, TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350(3): 221-231, doi: 10.1056/NEJMoa032441, indexed in Pubmed: 14724301.
Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012; 125(23): 2873-2891, doi: 10.1161/CIRCULATIONAHA.112.097014, indexed in Pubmed: 22586281.
Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012; 33(8): 977-987, doi: 10.1093/eurheartj/ehs036, indexed in Pubmed: 22362513.
Gada H, Kirtane AJ, Newman W, et al. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv. 2013; 6(12): 1263-1266, doi: 10.1016/j.jcin.2013.07.009, indexed in Pubmed: 24239202.
Serruys PW, Farooq V, Kalesan B, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013; 6(8): 777-789, doi: 10.1016/j. jcin.2013.04.011, indexed in Pubmed: 23968698.
Wijns W, Steg PhG, Mauri L, et al. PROTECT Steering Committee and Investigators. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. Eur Heart J. 2014; 35(40): 2812-2820, doi: 10.1093/eurheartj/ehu318, indexed in Pubmed: 25106761.
Sabaté M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet. 2016; 387(10016): 357-366, doi: 10.1016/s0140-6736(15)00548-6.
Valgimigli M, Sabate M, Kaiser C, et al. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ. 2014; 349(nov04 12): g6427-g6427, doi: 10.1136/bmj.g6427.
Valgimigli M, Borghesi M, Tebaldi M, et al. PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013; 34(12): 909-919, doi: 10.1093/eurheartj/ehs460, indexed in Pubmed: 23315904.
Valgimigli M, Tebaldi M, Borghesi M, et al. PRODIGY Investigators. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). JACC Cardiovasc Interv. 2014; 7(1): 20-28, doi: 10.1016/j. jcin.2013.09.008, indexed in Pubmed: 24332420.
Valgimigli M, Campo G, Percoco G, et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Am Heart J. 2010; 160(5): 804-811, doi: 10.1016/j.ahj.2010.07.034, indexed in Pubmed: 21095265.
Kereiakes D, Yeh R, Massaro J, et al. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC: Cardiovascular Interventions. 2015; 8(12): 1552-1562, doi: 10.1016/j.jcin.2015.05.026.
Valgimigli M, Patialiakas A, Thury A, et al. ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015; 65(8): 805-815, doi: 10.1016/j.jacc.2014.11.053, indexed in Pubmed: 25720624.
Ariotti S, Adamo M, Costa F, et al. ZEUS Investigators. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. JACC Cardiovasc Interv. 2016; 9(5): 426-436, doi: 10.1016/j.jcin.2015.11.015, indexed in Pubmed: 26965932.
Urban P, Meredith I, Abizaid A, et al. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med. 2015; 373(21): 2038-2047, doi: 10.1056/nejmoa1503943.
Bønaa KH, Mannsverk J, Wiseth R, et al. NORSTENT Investigators. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N Engl J Med. 2016; 375(13): 1242-1252, doi: 10.1056/NEJ-Moa1607991, indexed in Pubmed: 27572953.
Lipinski MJ, Escarcega RO, Baker NC, et al. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis. JACC Cardiovasc Interv. 2016; 9(1): 12-24, doi: 10.1016/j. jcin.2015.09.024, indexed in Pubmed: 26762906.
Mukete BN, van der Heijden LC, Tandjung K, et al. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies. Int J Cardiol. 2016; 221: 1087-1094, doi: 10.1016/j. ijcard.2016.07.101, indexed in Pubmed: 27448538.
Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016; 388(10059): 2479-2491, doi: 10.1016/S0140-6736(16)32050-5, indexed in Pubmed: 27806897.
Head SJ, Börgermann J, Osnabrugge RLJ, et al. Coronary artery bypass grafting: Part 2-optimizing outcomes and future prospects. Eur Heart J. 2013; 34(37): 2873-2886, doi: 10.1093/eurheartj/eht284, indexed in Pubmed: 24086086.
Head SJ, Kieser TM, Falk V, et al. Coronary artery bypass grafting: Part 1-the evolution over the first 50 years. Eur Heart J. 2013; 34(37): 2862-2872, doi: 10.1093/eurheartj/eht330, indexed in Pubmed: 24086085.
Lamy A, Devereaux PJ, Prabhakaran D, et al. CORONARY Investigators, CORONARY Investigators, CORONARY Investigators, CORONARY Investigators, CORONARY Investigators. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med. 2012; 366(16): 1489-1497, doi: 10.1056/NEJMoa1200388, indexed in Pubmed: 22449296.
Shroyer AL, Grover FL, Hattler B, et al. Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med. 2009; 361(19): 1827-1837, doi: 10.1056/NEJMoa0902905, indexed in Pubmed: 19890125.
Taggart DP, D'Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet. 2001; 358(9285): 870-875, doi: 10.1016/S0140-6736(01)06069-X, indexed in Pubmed: 11567701.
Taggart DP, Altman DG, Gray AM, et al. ART Investigators. Randomized Trial of Bilateral versus Single Internal-Thoracic-Artery Grafts. N Engl J Med. 2016; 375(26): 2540-2549, doi: 10.1056/NEJ-Moa1610021, indexed in Pubmed: 27959712.
Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg. 2013; 28(2): 109-116, doi: 10.1111/jocs.12074, indexed in Pubmed: 23488578.
Nocerino AG, Achenbach S, Taylor AJ. Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. Am J Cardiol. 2013; 112(10): 1576-1579, doi: 10.1016/j.amjcard.2013.07.017, indexed in Pubmed: 24035160.
Verma S, Goodman SG, Mehta SR, et al. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg. 2015; 15: 112, doi: 10.1186/s12893-015-0096-z, indexed in Pubmed: 26467661.
Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045-1057, doi: 10.1056/NEJ-Moa0904327, indexed in Pubmed: 19717846.
James SK, Roe MT, Cannon CP, et al. PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011; 342: d3527, doi: 10.1136/bmj.d3527, indexed in Pubmed: 21685437.
Lopes RD, Leonardi S, Neely B, et al. Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. J Am Coll Cardiol. 2016; 67(11): 1289-1297, doi: 10.1016/j.jacc.2016.01.034, indexed in Pubmed: 26988949.
Clemmensen P, Roe MT, Hochman JS, et al. TRILOGY ACS Investigators, TRILOGY ACS investigators, TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012; 367(14): 1297-1309, doi: 10.1056/NEJMoa1205512, indexed in Pubmed: 22920930.
Wiviott S, White H, Ohman E, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. The Lancet. 2013; 382(9892): 605-613, doi: 10.1016/s0140-6736(13)61451-8.
Guerra E, Ndrepepa G, Schulz S, et al. Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. Am Heart J. 2014; 168(6): 862-868.e1, doi: 10.1016/j.ahj.2014.08.015, indexed in Pubmed: 25458649.
Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17): 2344-2351, doi: 10.1161/CIRCULATIONAHA.106.685313, indexed in Pubmed: 17470709.
Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009; 30(22): 2714-2721, doi: 10.1093/eurheartj/ehp275, indexed in Pubmed: 19596658.
Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015; 36(47): 3320-3331, doi: 10.1093/eurheartj/ehv511, indexed in Pubmed: 26417060.
Adriaenssens T, Joner M, Godschalk TC, et al. Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators, PRESTIGE Consortium. PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort: PRESTIGE. Eur Heart J. 2014; 35(32): 2128-2129, indexed in Pubmed: 25289392.
Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. Circulation. 2016; 133(7): 650-660, doi: 10.1161/CIR-CULATIONAHA.115.019071, indexed in Pubmed: 26762519.
Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998; 339(23): 1665-1671, doi: 10.1056/NEJM199812033392303, indexed in Pubmed: 9834303.
Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334(17): 1084-1089, doi: 10.1056/NEJM199604253341702, indexed in Pubmed: 8598866.
Neumann FJ, Gawaz M, Ott I, et al. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol. 1996; 27(1): 15-21, doi: 10.1016/0735-1097(95)00433-5, indexed in Pubmed: 8522689.
Kastrati A, Schühlen H, Hausleiter J, et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation. 1997; 96(2): 462-467, indexed in Pubmed: 9244213.
Chaves AJ, Sousa AG, Mattos LA, et al. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial. Circulation. 2004; 109(7): 861-866, doi: 10.1161/01.CIR.0000116752.12261.D4, indexed in Pubmed: 14757690.
Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008; 371(9621): 1353-1363, doi: 10.1016/S0140-6736(08)60422-5, indexed in Pubmed: 18377975.
Steg PG, Harrington RA, Emanuelsson H, et al. PLATO Study Group. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013; 128(10): 1055-1065, doi: 10.1161/CIRCULATIONAHA.113.002589, indexed in Pubmed: 23900047.
Smolina K, Wright FL, Rayner M, et al. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012; 5(4): 532-540, doi: 10.1161/CIRCOUTCOMES.111.964700, indexed in Pubmed: 22740013.
Kernis SJ, Harjai KJ, Stone GW, et al. The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2003; 42(7): 1173-1177, doi: 10.1016/s0735-1097(03)00920-3, indexed in Pubmed: 14522475.
Murphy SA, Cannon CP, Wiviott SD, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15): 1495-1504, doi: 10.1056/NEJMoa040583, indexed in Pubmed: 15007110.
Budaj A, Yusuf S, Mehta SR, et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7): 494-502, doi: 10.1056/NEJMoa010746, indexed in Pubmed: 11519503.
Steinhubl SR, Berger PB, Mann JT, et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288(19): 2411-2420, doi: 10.1001/jama.288.19.2411, indexed in Pubmed: 12435254.
Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791-1800, doi: 10.1056/NEJMoa1500857, indexed in Pubmed: 25773268.
Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT Study Investigators. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016; 67(21): 2492-2502, doi: 10.1016/j.jacc.2016.03.485, indexed in Pubmed: 27046159.
Yeh RW, Kereiakes DJ, Steg PG, et al. DAPT Study Investigators. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015; 65(20): 2211-2221, doi: 10.1016/j. jacc.2015.03.003, indexed in Pubmed: 25787199.
Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016; 37(14): 1133-1142, doi: 10.1093/eur-heartj/ehv531, indexed in Pubmed: 26491109.
Mozaffarian D, Benjamin EJ, Go AS, et al. Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics- 2016 update: A report from the American Heart Association. Circulation. 2016; 133: e38-e360.
Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006; 114(8): 774-782, doi: 10.1161/CIRCULA-TIONAHA.106.612812, indexed in Pubmed: 16908769.
Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011; 32(15): 1854-1864, doi: 10.1093/eurheartj/ehr204, indexed in Pubmed: 21715717.
Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators, TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006; 152(4): 627-635, doi: 10.1016/j. ahj.2006.04.012, indexed in Pubmed: 16996826.
Bhatt DL, Fox KAA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16): 1706-1717, doi: 10.1056/NEJMoa060989, indexed in Pubmed: 16531616.
Bhatt DL, Flather MD, Hacke W, et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49(19): 1982-1988, doi: 10.1016/j.jacc.2007.03.025, indexed in Pubmed: 17498584.
Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016; 37(4): 390-399, doi: 10.1093/eurheartj/ehv443, indexed in Pubmed: 26324537.
Mauri L, Elmariah S, Yeh RW, et al. DAPT Study Investigators. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016; 37(4): 378-385, doi: 10.1093/eurhe-artj/ehv614, indexed in Pubmed: 26586780.
Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet. 2015; 385(9970): 792-798, doi: 10.1016/S0140-6736(14)62052-3, indexed in Pubmed: 25467565.
Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. The Lancet. 2015; 385(9985): 2371-2382, doi: 10.1016/s0140-6736(15)60263-x.
US Food and Drug Administration. FDA Drug Safety Communication: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death. http://www.fda.gov/Drugs/DrugSafety/ucm471286.htm (1 January 2017).
Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015; 65(13): 1298-1310, doi: 10.1016/j.jacc.2015.01.039, indexed in Pubmed: 25681754.
Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015; 350: h1618, doi: 10.1136/bmj.h1618, indexed in Pubmed: 25883067.
Bittl JA, Baber U, Bradley SM, et al. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016; 68(10): 1116-1139, doi: 10.1016/j.jacc.2016.03.512, indexed in Pubmed: 27036919.
Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012; 125(3): 505-513, doi: 10.1161/CIRCULATIO-NAHA.111.059022, indexed in Pubmed: 22179532.
Didier R, Morice MC, Barragan P, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015; 65(8): 777-786, doi: 10.1016/j. jacc.2014.11.008, indexed in Pubmed: 25461690.
Feres F, Costa RA, Abizaid A. Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents. JAMA. 2013, doi: 10.1001/jama.2013.282183.
Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015; 36(20): 1252-1263, doi: 10.1093/eurheartj/ehu523, indexed in Pubmed: 25616646.
Valgimigli M, Campo G, Monti M, et al. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012; 125(16): 2015-2026, doi: 10.1161/CIRCULATIONAHA.111.071589, indexed in Pubmed: 22438530.
Kim BK, Hong MK, Shin DH, et al. RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012; 60(15): 1340-1348, doi: 10.1016/j. jacc.2012.06.043, indexed in Pubmed: 22999717.
Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014; 64(20): 2086-2097, doi: 10.1016/j. jacc.2014.09.008, indexed in Pubmed: 25236346.
Han Y, Xu Bo, Xu K, et al. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial. Circ Cardiovasc Interv. 2016; 9(2): e003145, doi: 10.1161/CIR-CINTERVENTIONS.115.003145, indexed in Pubmed: 26858080.
Hong SJ, Shin DH, Kim JS, et al. IVUS-XPL Investigators. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. JACC Cardiovasc Interv. 2016; 9(14): 1438-1446, doi: 10.1016/j.jcin.2016.04.036, indexed in Pubmed: 27212028.
Nakamura M, Ako J, Shinke T, et al. 6 months versus 18 months dual antiplatelet treatment for patients underwent bioabsorbable polymer and abluminal coated DES deployment: NIPPON randomized study. European Society of Cardiology Scientific Session, Rome 2016. https://www.tctmd.com/slide/nipponrandomizedstudy-6-months-vs-18-months-dual-antiplatelet-treatmentpatientsunderwent (1 January 2017).
Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? Eur Heart J. 2015; 36(20): 1219-1222, doi: 10.1093/eurheartj/ehv053, indexed in Pubmed: 25761893.
Collet JP, Silvain J, Barthélémy O, et al. ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014; 384(9954): 1577-1585, doi: 10.1016/S0140-6736(14)60612-7, indexed in Pubmed: 25037988.
Park SJ, Kang SMo, Park DW, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010; 362(15): 1374-1382, doi: 10.1056/NEJMoa1001266, indexed in Pubmed: 20231231.
Helft G, Steg PG, Le Feuvre C, et al. OPTImal DUAL Antiplatelet Therapy Trial Investigators. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J. 2016; 37(4): 365-374, doi: 10.1093/eur-heartj/ehv481, indexed in Pubmed: 26364288.
Hermiller JB, Krucoff MW, Kereiakes DJ, et al. DAPT Study Investigators. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016; 9(2): 138-147, doi: 10.1016/j.jcin.2015.10.001, indexed in Pubmed: 26793956.
Park SJ, Lee CW, Ahn JM, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014; 129(3): 304-312, doi: 10.1161/CIR-CULATIONAHA.113.003303, indexed in Pubmed: 24097439.
Bonaca MP, Braunwald E, Sabatine MS. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015; 373(13): 1274-1275, doi: 10.1056/NEJMc1508692, indexed in Pubmed: 26398078.
Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23): 2736-2747, doi: 10.1161/CIRCULATIONA-HA.110.009449, indexed in Pubmed: 21670242.
Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987; 76(1): 142-154, indexed in Pubmed: 3109764.
GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993; 329(10): 673-682, doi: 10.1056/NEJM199309023291001, indexed in Pubmed: 8204123.
Hansson EC, Jidéus L, Åberg B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J. 2016; 37(2): 189-197, doi: 10.1093/eurheartj/ehv381, indexed in Pubmed: 26330426.
